Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to
evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P
glycoprotein [Pgp] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in
healthy participants.